All In MedTech

Device Trial Radar · NCT00526058

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Sep 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Aug 2007

Primary completion

Oct 2008

Study completion Dec 2008

Sponsor

Lead sponsor
B. Braun Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 6, 2007

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 25 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use under the approved indication of the acute reduction of LDL-cholesterol from the plasma in populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated.

Conditions

  • Hypercholesterolemia

Interventions

  • Secura then FuturaDevice

    Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.

  • Futura then SecuraDevice

    Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.Time frame: Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..

1 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hartford Hospital

    Hartford, Connecticut

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.